Open Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 +/- ribavirin (RBV) in the treatment of Hepatitis C G1 and 4, in patients either eligible for liver transplant (HCC) or curative therapy or non-eligible for curative therapy but clinically stable disease post local resection, embolization or ablative therapy: HATCHeT Study - HepATocellular Cancer Hcv Therapy Study.